From the Desk of Steve Strazza @Sstrazza
The market keeps squeezing short sellers out of their biotech positions and rewarding bulls with big breakouts.
Knowing this, our strategy is simple. We want to keep buying the best-looking and most heavily-shorted biotech stocks.
Today, we're covering one that has rallied nearly 200% since late last year. Despite this extreme upside momentum, the stock still has a massive short interest.
With the stock resolving a multi-year accumulation pattern, we think this short squeeze has plenty of room to run. To get back to the all-time highs from just a few years ago, it would require about a 10x.
We're looking for something much smaller and quicker for now, but you never know!
Let's talk about how we're trading our latest Freshly Squeezed setup.